SCHEMBL6277100

SCHEMBL6277100

CC(c1ccncc1NC(=O)c1ccc(F)cc1)C1NC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
ABL1 P00519 7/20 0.38
MAPT P10636 2/20 0.37
NAMPT P43490 1/20 0.36
TRPV1 Q8NER1 3/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
LIPE Q05469 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174987 0.94 GAA (0.41) GSK3AGSK3BABL1MAPTNPC1
SCHEMBL6171763 0.88 LMNA (0.38) GSK3AGSK3BABL1MAPTTRPV1
SCHEMBL6176663 0.88 LMNA (0.39) GSK3AGSK3BABL1MAPTTRPV1
SCHEMBL6175153 0.87 LIPE (0.43) GSK3AGSK3BABL1LIPE
SCHEMBL6174779 0.86 LMNA (0.36) GSK3AGSK3BABL1MAPTTRPV1
SCHEMBL6177285 0.85 TDP1 (0.42) GSK3AGSK3BMAPTLIPE
SCHEMBL6174451 0.85 LMNA (0.40) GSK3AGSK3BABL1TRPV1LIPE
SCHEMBL6173186 0.84 LMNA (0.40) MAPTNPC1RAB9ALIPE
SCHEMBL6175831 0.84 NPC1 (0.46) NPC1RAB9A
SCHEMBL6172197 0.84 LMNA (0.40) MAPTNPC1RAB9ALIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed